COMPANY RESEARCHOffers integrated structural biology, AI design, cyclic peptide synthesis, DMPK, and process-development capabilities. A September 2026 company article discusses oral cyclic peptide bioavailability, impurity control, and scale-up.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY IFRS / consolidated | 1,729,446,000 | 219,761,000 Net income/(loss) attributable to owners of the parent | 232,225,000 | Original ↗ |
| 2026H1 2026-06-30 | CNY IFRS / consolidated / unaudited interim | 1,006,519,000 | 80,077,000 Net income/(loss) attributable to owners of the parent | 346,028,000 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
Offers integrated structural biology, AI design, cyclic peptide synthesis, DMPK, and process-development capabilities. A September 2026 company article discusses oral cyclic peptide bioavailability, impurity control, and scale-up.
A dedicated PROTAC / molecular glue page lists protein production, crystallography, screening, binding kinetics, drug metabolism, bioassays, and AIDD/CADD, plus custom PROTAC design and synthesis.
Combines structural biology and discovery CRO, Langhua CDMO/CMC, and incubation/investment. Investment fair-value changes affect group profit.
Listed as HKEX 01873; original 2025 annual and 2026H1 reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Cyclic peptide discovery and development services | Client-dependent · Client-dependent | 未披露 | Client results not disclosed |
| Structure-based PROTAC / molecular glue discovery and synthesis | Program-dependent / not disclosed · Determined by the collaboration program | Platform / services | This record does not claim platform-wide human validation |
| CRO / CDMO / incubation platform | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.